The 2018 10th Symposium on “Voice and Responsibility” of NPC Representatives and CPPCC Members in Pharmaceutical Industry Held in Beijing

  • 2018-03-08

At the afternoon of March 4, 2018, the 2018 10th Symposium on “Voice and Responsibility” of NPC Representatives and CPPCC Members in Pharmaceutical Industry (the Symposium) organized by 25 pharmaceutical associations (societies) in China's pharmaceutical industry including Chinese Pharmaceutical Enterprises Association (CPEA) and China Pharmaceutical Industry Association (CPIA) was held in Beijing. More than 40 representatives and members from the NPC and CPPCC Conference attended the meeting and provided advice and suggestions for the development of the pharmaceutical industry in 2018. At the same time, Heads of the Department of Drug and Cosmetics Registration and the Department of Drug and Cosmetics Supervision of CFDA, the State Council Medical Reform Office, and Medical Insurance Department of the Ministry of Human Resources and Social Security also attended the Symposium.

The Symposium on “Voice and Responsibility” of NPC Representatives and CPPCC Members in Pharmaceutical Industry has been held 10 times as of this year. According to preliminary statistics, a total of 330 NPC Representatives and CPPCC Members have attended the previous 9 symposiums. A total of 673 opinions and suggestions submitted by the grass-roots pharmaceutical enterprises and institutions have been collected, 16 of which have been collected and refined as proposal material. Most of such proposal material was signed and reported as opinion bills which was seriously discussed by relevant government departments who have given feedbacks and replies, and were used as an important reference for government departments to reform and improve their administration.

Since the Party Central Committee and the State Council vigorously promoted reforms in drug supervision in 2015, the China Food and Drug Administration (CFAD) has implemented the Four Most Stringent Requirements, strengthened the supervision of the entire pharmaceutical process, and promoted reforms and innovations in the examination and approval system for drugs. As a result, it has launched a series of policies and initiatives and delivered excellent top-level design, covering all sectors from drug R & D to its listing.

Search